Strides Pharma Science has informed about Press Release issued by the Company titled: USFDA announces Laboratory testing and analysis of Ranitidine and issues statement with acceptable NDMA limits. Strides’ Ranitidine Tablets 300 mg lots tested by USFDA are within the acceptable NDMA limits.
The above information is a part of company’s filings submitted to BSE.